Bristol Myers Squibb has announced new clinical trial data for its leukemia CAR-T cell therapy Breyanzi. The data shows that the therapy has met its primary endpoint in the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL), beating standard care in complete response rate. Bristol Meyer intends to present the data at an upcoming conference.
According to Paul Schloesser, “The therapy, acquired by Bristol Myers when it bought out Celgene for $74 billion in 2019, was first approved back in 2021 for pre-treated diffuse large B cell lymphoma, with expansions since then into more lymphoma indications. And while a spokesperson told Endpoints that the Big Pharma is pursuing opportunities to expand Breyanzi even more, Bristol Myers’ head of cell therapy development Anne Kerber said in the trial announcement Thursday that with CLL’s “complex biology and immune dysregulation,” the currently incurable disease makes developing T cell-based therapies for CLL “very challenging.””
To read more, click here.
(Source: Endpoints News, January 26th, 2023)